|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
0.00% | - |
| 30/12 | Biora Therapeutics, Inc. Went Out of Business | CI |
| 27/25/27 | Motion For Case Conversion Approved for Biora Therapeutics, Inc. | CI |
| Capitalization | 8L 7L 6L 6L 11.16L 7.41Cr 11.67L 73.77L 29.21L 3.57Cr 30.69L 30.06L 13Cr | P/E ratio 2022 |
-0.66x | P/E ratio 2023 | -0.17x |
|---|---|---|---|---|---|
| Enterprise value | 3.34Cr 2.83Cr 2.59Cr 2.46Cr 4.56Cr 302.9Cr 4.77Cr 30Cr 12Cr 145.82Cr 13Cr 12Cr 524.92Cr | EV / Sales 2022 |
422x | EV / Sales 2023 | 17,337x |
| Free-Float |
98.28% | Yield 2022 * |
-
| Yield 2023 | - |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
More news
| 1 day | -99.00% |
| 1 month | 0 | 0 | |
| Current year | 0 | 0 | |
| 1 year | 0 | 0.34 | |
| 3 years | 0 | 67 | |
| 5 years | 0 | 1,583.08 | |
| 10 years | 0 | 3,980 |
| Manager | Title | Age | Since |
|---|---|---|---|
Adi Mohanty
CEO | Chief Executive Officer | 59 | 08/11/2021 |
Eric d'Esparbes
CEO | Chief Executive Officer | 58 | 01/09/2021 |
Ariella Kelman
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Alter
CHM | Chairman | 63 | 01/11/2021 |
Lynne Powell
BRD | Director/Board Member | 59 | 01/02/2019 |
| Director/Board Member | 51 | 01/06/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -99.00% | 0.00% | - | - | 4 | ||
| -0.66% | -3.17% | +9.09% | +97.32% | 5.03TCr | ||
| +0.74% | +2.76% | +68.18% | +7.83% | 4.21TCr | ||
| -0.77% | -4.47% | +87.44% | +656.87% | 3.2TCr | ||
| +1.02% | -6.27% | -9.34% | -24.46% | 2.68TCr | ||
| +1.49% | +6.64% | +75.41% | -41.80% | 2TCr | ||
| +0.23% | -6.03% | +43.62% | -29.28% | 1.91TCr | ||
| -0.95% | +4.49% | +131.22% | - | 1.26TCr | ||
| +0.79% | +0.79% | +57.55% | +118.24% | 1.19TCr | ||
| Average | -10.80% | -1.67% | +57.90% | +112.10% | 2.39TCr | |
| Weighted average by Cap. | +0.15% | -1.22% | +49.15% | +126.59% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 3L 3L 2L 2L 4L 2.76Cr 4L 27.5L 10.89L 1.33Cr 11.44L 11.2L 4.79Cr | 4T 3.39T 3.1T 2.94T 5.46T 4L 5.71T 36.06T 14.28T 2L 15T 14.69T 6L |
| Net income | -3.82Cr -3.23Cr -2.96Cr -2.8Cr -5.21Cr -345.69Cr -5.44Cr -34Cr -14Cr -166.42Cr -14Cr -14Cr -599.07Cr | -12Cr -11Cr -9.63Cr -9.12Cr -17Cr -1.12TCr -18Cr -111.9Cr -44Cr -541.32Cr -47Cr -46Cr -1.95TCr |
| Net Debt | 9.93Cr 8.4Cr 7.7Cr 7.29Cr 14Cr 899.3Cr 14Cr 89Cr 35Cr 432.93Cr 37Cr 36Cr 1.56TCr | 3.26Cr 2.76Cr 2.53Cr 2.4Cr 4.45Cr 295.49Cr 4.65Cr 29Cr 12Cr 142.25Cr 12Cr 12Cr 512.08Cr |
More financial data
* Estimated data
Employees
58
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIORQ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















